Compare LZM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | MNPR |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Isle of Man | United States |
| Employees | 142 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.4M | 372.9M |
| IPO Year | N/A | 2019 |
| Metric | LZM | MNPR |
|---|---|---|
| Price | $4.43 | $56.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $7.00 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 193.9K | 150.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $510.94 | N/A |
| Revenue Next Year | $217.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $26.06 |
| 52 Week High | $6.23 | $105.00 |
| Indicator | LZM | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 47.26 |
| Support Level | $4.13 | $56.15 |
| Resistance Level | $4.42 | $61.30 |
| Average True Range (ATR) | 0.26 | 3.32 |
| MACD | 0.02 | 0.79 |
| Stochastic Oscillator | 51.33 | 60.22 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.